Table 3.

Longitudinal common carotid artery intima-media thickness associations with baseline and week 24 or 48 biomarker in successfully treated population.

Additional annualized rate of IMT (μm/year) per unit change in biomarker (95% confidence interval)
	Baseline biomarker^a		Week 24 or 48 biomarker^b
		P		P
Homeostasis model assessment of insulin resistance (log₁₀)	5.27 (–0.29, 10.83)	0.06	1.56 (–3.63, 6.74)	0.55
Non-high-density lipoprotein cholesterol (per 30mg/dl)	1.24 (–0.62, 3.09)	0.19	2.22 (0.52, 3.93)	0.011
D-dimer (log₁₀ μg/ml)	1.97 (–2.10, 6.04)	0.34	1.08 (–2.92, 5.08)	0.60
High sensitivity C-reactive protein (log₁₀ μ/ml)	3.93 (–0.18, 8.04)	0.06	–0.96 (–4.29, 2.37)	0.57
Interleukin-6 (log₁₀ pg/ml)	2.54 (–4.29, 9.37)	0.46	–2.27 (–6.53, 1.98)	0.29
Soluble CD14 (log₁₀ ng/ml)	3.03 (–14.75, 20.81)	0.74	4.37 (–14.39, 23.12)	0.65
Soluble CD163 (log₁₀ ng/ml)	4.93 (–3.36, 13.22)	0.24	0.36 (–10.92, 11.64)	0.95
GlycA (μmol/l)	–0.00 (–0.03, 0.02)	0.94	–0.01 (–0.03, 0.02)	0.67
GlycB (μmol/l)	0.03 (–0.04, 0.11)	0.37	0.03 (–0.03, 0.09)	0.41
%CD4⁺: CD38⁺HLADR⁺ T cells	–0.07 (–0.20, 0.06)	0.28	–0.15 (–0.34, 0.05)	0.15
%CD8⁺: CD38⁺HLADR⁺ T cells	–0.05 (–0.18, 0.08)	0.45	–0.12 (–0.28, 0.03)	0.12
%CD14⁺CD16⁺ monocytes	–0.05 (–0.25, 0.15)	0.63	0.02 (–0.14, 0.17)	0.83

IMT, intima-media thickness.

Analyses adjusted for screening HIV-1 RNA level and Framingham risk scores, baseline common carotid artery intima-media thickness (μm), and baseline biomarker.

Analyses adjusted for screening HIV-1 RNA level and Framingham risk scores and baseline common carotid artery intima-media (μm).